Replies to post #14213 on Ariad Pharmaceuticals Inc fka ARIA

[biomaven0]

what's baked in to the current market cap

Ponatinib approval for 3rd-line. 80% chance of rida approval. Nothing for '113 or rida combination therapy.

In terms of near-term catalysts there is the updated data at ASH (unlikely to move the stock much either way) and maybe an Asia partnership.

Peter